Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review

Author(s): Adriana Mares, Tayana Rodriguez, Abhizith Deoker, Angelica Lehker and Debabrata Mukherjee*

Volume 20, Issue 1, 2022

Published on: 20 July, 2021

Page: [46 - 51] Pages: 6

DOI: 10.2174/1570161119666210720120439

Price: $65

Abstract

Background: Heart failure is a major cause of morbidity and mortality globally. By the end of this decade, ~8 million Americans will have heart failure with an expenditure of $69.8 billion.

Objective: In this narrative review, we evaluate the benefits, potential risks and the role of Mineralocorticoid Receptor Antagonists (MRAs) in the management of both Heart Failure with Preserved Ejection Fraction (HFpEF) and Heart Failure with Reduced Ejection Fraction (HFrEF).

Methods: We performed a comprehensive literature review to assess the available evidence on the role of MRAs in heart failure using the online databases (PubMed, Embase, Scopus, CINAHL and Google Scholar).

Results: Clinical evidence shows that MRAs such as spironolactone and eplerenone reduce mortality and readmissions for patients with HFrEF compared with placebo. Furthermore, one trial reported that MRAs reduce heart failure hospitalization in patients with HFpEF. The American College of Cardiology/American Heart Association Guidelines strongly recommend using MRA in patients with reduced Left Ventricular Ejection Fraction (LVEF) with Class II-IV symptoms, estimated glomerular filtration rate >30 ml/min/1.73 m2, and absence of hyperkalemia. Despite this, MRAs are underutilized in the management of heart failure.

Conclusions: MRAs improve outcomes in patients with both HFpEF and HFrEF but remain underutilized.

Keywords: Heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, mineralocorticoid receptor antagonists, heart failure, left ventricular ejection fraction, readmission.

« Previous Next »
Graphical Abstract

[1]
Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: A report from the American heart association. Circulation 2021; 143(8): e254-743.
[http://dx.doi.org/10.1161/CIR.0000000000000950] [PMID: 33501848]
[2]
Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes. Circulation 2012; 126(1): 65-75.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.080770] [PMID: 22615345]
[3]
Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: Changing mortality over the last 30 years. Eur J Heart Fail 2014; 16(3): 317-24.
[http://dx.doi.org/10.1002/ejhf.16] [PMID: 24464640]
[4]
Chang PP, Wruck LM, Shahar E, et al. Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC study community surveillance. Circulation 2018; 138(1): 12-24.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.027551] [PMID: 29519849]
[5]
Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013; 6(3): 606-19.
[http://dx.doi.org/10.1161/HHF.0b013e318291329a] [PMID: 23616602]
[6]
GBD 2019 diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258): 1204-22.
[http://dx.doi.org/10.1016/S0140-6736(20)30925-9] [PMID: 33069326]
[7]
Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013; 34(19): 1424-31.
[http://dx.doi.org/10.1093/eurheartj/eht066] [PMID: 23470495]
[8]
Bozkurt B, Coats A, Tsutsui H. Universal definition and classification of heart failure. J Card Fail 2021; 1: 1-27.
[9]
Pitt B, Pedro Ferreira J, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: Current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 2017; 3(1): 48-57.
[http://dx.doi.org/10.1093/ehjcvp/pvw016] [PMID: 27530337]
[10]
Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 1991; 88(4): 1141-6.
[http://dx.doi.org/10.1172/JCI115414] [PMID: 1918369]
[11]
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Circulation 2000; 102(22): 2700-6.
[http://dx.doi.org/10.1161/01.CIR.102.22.2700] [PMID: 11094035]
[12]
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309-21.
[http://dx.doi.org/10.1056/NEJMoa030207] [PMID: 12668699]
[13]
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11-21.
[http://dx.doi.org/10.1056/NEJMoa1009492] [PMID: 21073363]
[14]
Ferreira JP, Verdonschot J, Wang P, et al. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail 2021; 9(4): 268-77.
[http://dx.doi.org/10.1016/j.jchf.2020.11.010] [PMID: 33549556]
[15]
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709-17.
[http://dx.doi.org/10.1056/NEJM199909023411001] [PMID: 10471456]
[16]
Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383-92.
[http://dx.doi.org/10.1056/NEJMoa1313731] [PMID: 24716680]
[17]
Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309(8): 781-91.
[http://dx.doi.org/10.1001/jama.2013.905] [PMID: 23443441]
[18]
Kapelios CJ, Murrow JR, Nührenberg TG, Montoro Lopez MN. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 2019; 24(3): 367-77.
[http://dx.doi.org/10.1007/s10741-018-9758-0] [PMID: 30618017]
[19]
Chatterjee S, Moeller C, Shah N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012; 125(8): 817-25.
[http://dx.doi.org/10.1016/j.amjmed.2011.12.018] [PMID: 22840667]
[20]
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351(6): 543-51.
[http://dx.doi.org/10.1056/NEJMoa040135] [PMID: 15295047]
[21]
Sica DA. Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovasc J 2015; 11(4): 235-9.
[http://dx.doi.org/10.14797/mdcj-11-4-235] [PMID: 27057293]
[22]
Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 2015; 24(5): 417-24.
[http://dx.doi.org/10.1097/MNH.0000000000000147] [PMID: 26083526]
[23]
Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 2013; 34(31): 2453-63.
[http://dx.doi.org/10.1093/eurheartj/eht187] [PMID: 23713082]
[24]
Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37(27): 2105-14.
[http://dx.doi.org/10.1093/eurheartj/ehw132] [PMID: 27130705]
[25]
Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64(1): 69-78.
[http://dx.doi.org/10.1097/FJC.0000000000000091] [PMID: 24621652]
[26]
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383(23): 2219-29.
[http://dx.doi.org/10.1056/NEJMoa2025845] [PMID: 33264825]
[27]
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-200.
[http://dx.doi.org/10.1093/eurheartj/ehw128] [PMID: 27206819]
[28]
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16): e147-239.
[http://dx.doi.org/10.1016/j.jacc.2013.05.019] [PMID: 23747642]
[29]
Patterson SJ, Reaves AB, Tolley EA, et al. Underutilization of aldosterone antagonists in heart failure. Hosp Pharm 2017; 52(10): 698-703.
[http://dx.doi.org/10.1177/0018578717724886] [PMID: 29276242]
[30]
Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009; 302(15): 1658-65.
[http://dx.doi.org/10.1001/jama.2009.1493] [PMID: 19843900]
[31]
Durstenfeld MS, Katz SD, Park H, Blecker S. Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: A single-center retrospective cohort study. BMC Cardiovasc Disord 2019; 19(1): 194.
[http://dx.doi.org/10.1186/s12872-019-1175-3] [PMID: 31399059]

Rights & Permissions Print Cite
Article Metrics
45
2
© 2024 Bentham Science Publishers | Privacy Policy